Skip to content
Skip to navigation
Skip to footer

Archive

View global media contacts

Home / Media Centre / Archive

Here you can find the archive of all Press Releases prior to 2022

Filter by date:

Showing 1107 press releases before 2022

Acalabrutinib recommended for orphan drug designation in Europe for three indications
25 February 2016
Zurampic (lesinurad) approved in the European Union for patients with gout
19 February 2016
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
19 February 2016
Durvalumab granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer
17 February 2016
AstraZeneca and MedImmune enter consortium to deliver new treatments for chronic kidney disease
11 February 2016
Full-Year and Q4 2015 Results
4 February 2016
TAGRISSO™ (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
3 February 2016
AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma
2 February 2016
Lynparza™ (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer
28 January 2016
AstraZeneca partners with peers and academia to establish translational research fund
25 January 2016

<
58
59
60
61
62
63
64
111
>

All of our latest press releases and articles are available to explore